Hi-Tech Deal Broadens Akorn Consumer Business
This article was originally published in The Tan Sheet
Executive Summary
Akorn’s $650 million acquisition of Hi-Tech Pharmacal provides a potential long-term platform for Rx-to-OTC switches and offers additional OTC cross-selling opportunities with retailers. Akorn CEO Raj Rai calls the transaction a “transformative event” that will be instantly accretive for the firm.
You may also be interested in...
Bausch + Lomb Buy Vaults Valeant Into Consumer Eye Care Space
Bausch + Lomb retains its name and becomes a division of Valeant in the $8.7 billion acquisition expected to close in the 2013 third quarter.
Novartis Wraps Up Alcon Ownership, Forms New Eye Care Unit
Novartis will create an eye care division, its second-largest unit and the fifth growth platform in its health care portfolio, with full ownership of Alcon, the world's largest eye care company.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.